HCV Resistance Profile Evolution in a GT1b, DAA‐Naive Patient Before, On, and After Failing Triple DAA Therapy

[1]  Christoph Sarrazin,et al.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. , 2016, Journal of hepatology.

[2]  S. Zeuzem,et al.  Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients , 2015, PloS one.

[3]  K. Chayama,et al.  Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis , 2015, Hepatology.

[4]  T. Pilot‐Matias,et al.  Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir , 2015, Antimicrobial Agents and Chemotherapy.

[5]  V. de Lédinghen,et al.  Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). , 2015, The Lancet. Infectious diseases.

[6]  H Abe,et al.  Emergence of resistant variants detected by ultra‐deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1 , 2015, Journal of viral hepatitis.

[7]  Eoin Coakley,et al.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.

[8]  Stefan Zeuzem,et al.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. , 2014, The New England journal of medicine.